Easl
Membership Organizations · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Rue Daubin 7, Geneva, Geneva, 1203, Swit...Phone Number
+41 228070360Website
www.easl.euRevenue
$12 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Easl
EASL, the European Association for the Study of the Liver, is dedicated to hepatology, aiming to empower practitioners in the treatment and prevention of liver diseases. The organization offers various services including membership benefits, education, advocacy, and guidelines to support healthcare professionals and researchers. EASL organizes events, including congresses and masterclasses, to foster collaboration and knowledge sharing in the field of hepatology. Their target audience includes healthcare practitioners, researchers, and policymakers involved in liver health.Explore more
Easl Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Easl your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Easl has new funding data
Congratulate Masked Content for being promoted to Masked Content at Easl
Website visits: Recent activity has been detected on your website
Easl, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Easl recently announced quarterly report
Check out if Easl is spiking on competitors!
Check if Easl has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Easl launches new products
Click to see if Easl had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Easl is experiencing very low activity levels compared to other companies in the Organizations sector.
What does this means?
Easl is drawing exceptional interest within the Organizations industry, suggesting notable developments or strong market momentum, learn more about Easl.
Easl Tech Stack
A closer look at the technologies used by Easl
See more technologies
Easl News & Media
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
New translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection BRII-179 as add-on therapy induces functional antibody responses and contributes to improved sustained HBsAg loss in PEG-IFNa-treated participants with chronic HBV infection DURHAM, N.C. and BEIJING, June 7, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology c89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
-Poster presentation selected for the EASL Poster Tour, a dedicated discussion session- -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a clinical abstract titled “Thermoacoustic assessment of fatty liver disease - a clinical feasibility study” for presentation at the Steatotic Liver Disease Summit™ 2023 hosted by the European Association for the Study of the Liver (EASL), taking place September 21-23 in Prague, Czechoslovakia. “This poster preseAscletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023
HANGZHOU and SHAOXING, China, June 25, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated interferon (PEG-IFN) and entecavir (ETV) in chronic...
Read more news
Top Membership Organizations Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Easl
Sign Up For FreeTo access detailed company insights
EASL, the European Association for the Study of the Liver, is dedicated to hepatology, aiming to empower practitioners in the treatment and prevention of liver diseases. The organization offers various services including membership benefits, education, advocacy, and guidelines to support healthcare professionals and researchers. EASL organizes even... Read More
